Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER + breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Periyasamy Thandavan, Sudharsan ^a   Takhar, Suchreet ^a   Singer, Adam ^a   Dohn, Michael R ^b   Jackson, William H ^a   Welborn, April E ^a   LeRoith, Derek ^c   Marrero, Mario ^a   Thangaraju, Muthusamy ^a   Huang, Shuang ^a   Schoenlein, Patricia V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ANTIESTROGEN; ANTIGESTAGEN; BH3 PROTEIN; BIM PROTEIN; COMPLEMENTARY DNA; CYTOKERATIN 18; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SOMATOMEDIN B; TAMOXIFEN; TRYPAN BLUE; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; DRUG DERIVATIVE; ENZYME INHIBITOR; ESTROGEN RECEPTOR; HORMONE ANTAGONIST; HYDROXYTAMOXIFEN; MAP2K1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MIFEPRISTONE; ONCOPROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; CELL DEATH; CELL DIVISION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HORMONE ANTAGONISTS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE KINASE 1; MEMBRANE PROTEINS; MIFEPRISTONE; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84862795381     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3153     Document Type: Article

References (67)

1. Cutler W, Burki R, Genovesse E, Zacher M. Breast cancer in postmenopausal women: what is the real risk?. Fertil Steril 2009, 92:S16.
2. SEER Cancer Statistics Review, 1975-2007. 2009, Bethesda, MD: National Cancer Institute, Altekruse SFKC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK.
3. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007, 25:5815-5824. 10.1200/JCO.2007.11.3886, 17893378.
4. Herynk MH, Fuqua SA. Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol 2007, 608:130-143. 10.1007/978-0-387-74039-3_10, 17993238.
5. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
6. Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, Jackson WH, Barrett JT. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance. Autophagy 2009, 5:400-403. 10.4161/auto.5.3.7784, 19221464.
7. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011, 125:13-22. 10.1016/j.jsbmb.2011.02.001, 21335088.
8. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004, 10:2751-2760. 10.1158/1078-0432.CCR-03-0141, 15102680.
9. Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000, 65:825-830. 10.1016/S0039-128X(00)00195-1, 11108894.
10. Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 2007, 67:9929-9936. 10.1158/0008-5472.CAN-07-1103, 17942925.
11. El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 1998, 49:109-117. 10.1023/A:1006098910000, 9696393.
12. Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 2008, 23:2072-2079. 10.1093/humrep/den228, 18579510.
13. Schoenlein PV, Hou M, Samaddar JS, Gaddy VT, Thangaraju M, Lewis J, Johnson M, Ganapathy V, Kallab A, Barrett JT. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol 2007, 31:643-655.
14. El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998, 51:149-168. 10.1023/A:1006078032287, 9879777.
15. Bardon S, Vignon F, Montcourrier P, Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 1987, 47:1441-1448.
16. Thomas M, Monet JD. Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 1992, 75:865-870. 10.1210/jc.75.3.865, 1517379.
17. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 2004, 10:5215-5225. 10.1158/1078-0432.CCR-03-0637, 15297425.
18. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 2009, 74:586-594. 10.1016/j.steroids.2008.11.020, 19138696.
19. Neuenschwander S, Roberts CT, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995, 136:4298-4303. 10.1210/en.136.10.4298, 7664648.
20. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008, 13:3273-3287.
21. Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 2000, 11:99-110.
22. Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH. BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. J Biol Chem 2002, 277:33422-33430. 10.1074/jbc.M201147200, 12082091.
23. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905-2927. 10.1101/gad.13.22.2905, 10579998.
24. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120:2406-2413. 10.1172/JCI41680, 2898598, 20530877.
25. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529. 10.1056/NEJMoa1109653, 22149876.
26. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002, 21:4000-4008. 10.1038/sj.onc.1205506, 12037682.
27. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001, 95:247-254. 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S, 11400118.
28. Donovan JC, Milic A, Slingerland JM. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001, 276:40888-40895. 10.1074/jbc.M106448200, 11527971.
29. Hong W, Chen L, Li J, Yao Z. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells. Biochem Biophys Res Commun 2010, 396:299-303. 10.1016/j.bbrc.2010.04.085, 20406620.
30. Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT, Schoenlein PV. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 2008, 7:2977-2987. 10.1158/1535-7163.MCT-08-0447, 18790778.
31. Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy 2010, 6:19-35. 10.4161/auto.6.1.10323, 20110775.
32. O'Reilly LA, Kruse EA, Puthalakath H, Kelly PN, Kaufmann T, Huang DC, Strasser A. MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. J Immunol 2009, 183:261-269. 10.4049/jimmunol.0803853, 2950174, 19542438.
33. Yao Z, Flash I, Raviv Z, Yung Y, Asscher Y, Pleban S, Seger R. Non-regulated and stimulated mechanisms cooperate in the nuclear accumulation of MEK1. Oncogene 2001, 20:7588-7596. 10.1038/sj.onc.1204963, 11753637.
34. Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Haussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P. 17-Allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol Cancer Ther 2010, 9:1378-1395. 10.1158/1535-7163.MCT-09-1131, 2868106, 20442308.
35. Tian N, Arany I, Waxman DJ, Baliga R. Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells. Kidney Int 2010, 78:182-190. 10.1038/ki.2010.100, 3053138, 20407477.
36. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995, 49:415-421. 10.1016/0753-3322(96)82678-3, 8746077.
37. Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, Shoshan M, Linder S. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002, 20:253-259. 10.1023/A:1016249728664, 12201488.
38. Prasad V, Chandele A, Jagtap JC, Sudheer Kumar P, Shastry P. ROS-triggered caspase 2 activation and feedback amplification loop in beta-carotene-induced apoptosis. Free Radic Biol Med 2006, 41:431-442. 10.1016/j.freeradbiomed.2006.03.009, 16843824.
39. Oh YI, Kim JH, Kang CW. Oxidative stress in MCF-7 cells is involved in the effects of retinoic acid-induced activation of protein kinase C-delta on insulin-like growth factor-I secretion and synthesis. Growth Horm IGF Res 2010, 20:101-109. 10.1016/j.ghir.2009.10.003, 19932628.
40. Ripple MO, Kalmadi S, Eastman A. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat 2005, 93:177-188. 10.1007/s10549-005-4794-6, 16187238.
41. Whyte J, Bergin O, Bianchi A, McNally S, Martin F. Key signalling nodes in mammary gland development and cancer: mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 2009, 11:209. 10.1186/bcr2361, 2790844, 19818165.
42. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90:859-869. 10.1016/S0092-8674(00)80351-7, 9298898.
43. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351:95-105. 10.1042/0264-6021:3510095, 1221339, 10998351.
44. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993, 53:3736-3740.
45. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009, 16:368-377. 10.1038/cdd.2008.148, 18846109.
46. Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ. Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 2004, 279:8837-8847. 10.1074/jbc.M311578200, 14681225.
47. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, Huang DC. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998, 17:384-395. 10.1093/emboj/17.2.384, 1170389, 9430630.
48. Yamaguchi T, Okada T, Takeuchi K, Tonda T, Ohtaki M, Shinoda S, Masuzawa T, Ozawa K, Inaba T. Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator. Gene Ther 2003, 10:375-385. 10.1038/sj.gt.3301897, 12601392.
49. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8:397-403. 10.1016/S0962-8924(98)01346-4, 9789328.
50. Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 2011, doi: 10.1002/cncr.26407.
51. Roberts CG, Millar EK, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M, Tobelmann P, McCloy RA, Musgrove EA, Sutherland RL, Butt AJ. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 2011, 30:3186-3197. 10.1038/onc.2011.36, 21383694.
52. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003, 278:49795-49805. 10.1074/jbc.M309523200, 14527951.
53. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990, 11:266-301. 10.1210/edrv-11-2-266, 2114281.
54. Wiehle RD, Christov K, Mehta R. Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep 2007, 18:167-174.
55. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006, 314:1467-1470. 10.1126/science.1130471, 17138902.
56. Tworoger SS, Rosner BA, Willett WC, Hankinson SE. The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 2011, 13:R99. 10.1186/bcr3040, 3262212, 22017816.
57. Sivaprasad U, Basu A. Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-alpha-induced cell death in MCF-7 cells. J Cell Mol Med 2008, 12:1265-1271. 10.1111/j.1582-4934.2008.00282.x, 18266953.
58. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH, Sussenbach JS. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997, 272:31163-31171. 10.1074/jbc.272.49.31163, 9388270.
59. Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK, Zborowska E, Brattain MG. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells. J Cell Physiol 1998, 176:424-434. 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.0.CO;2-1, 9648930.
60. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 2010, 5:e13026. 10.1371/journal.pone.0013026, 2946397, 20885957.
61. Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y, Zwart A, Nehra R, Liu MC. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol 2009, 114:8-20. 10.1016/j.jsbmb.2008.12.023, 2768542, 19444933.
62. Hubner A, Barrett T, Flavell RA, Davis RJ. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 2008, 30:415-425. 10.1016/j.molcel.2008.03.025, 2453504, 18498746.
63. Payre B, de Medina P, Boubekeur N, Mhamdi L, Bertrand-Michel J, Terce F, Fourquaux I, Goudouneche D, Record M, Poirot M, Silvente-Poirot S. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther 2008, 7:3707-3718. 10.1158/1535-7163.MCT-08-0507, 19074846.
64. de Medina P, Silvente-Poirot S, Poirot M. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 2009, 5:1066-1067. 10.4161/auto.5.7.9820, 19738414.
65. de Medina P, Paillasse MR, Segala G, Khallouki F, Brillouet S, Dalenc F, Courbon F, Record M, Poirot M, Silvente-Poirot S. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chem Phys Lipids 2011, 164:432-437. 10.1016/j.chemphyslip.2011.05.005, 21641337.
66. Wen YY, Yang ZQ, Song M, Li BL, Yao XH, Chen XL, Zhao J, Lu YY, Zhu JJ, Wang EH. The expression of SIAH1 is downregulated and associated with Bim and apoptosis in human breast cancer tissues and cells. Mol Carcinog 2010, 49:440-449.
67. Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ 2010, 17:1624-1635. 10.1038/cdd.2010.41, 2914832, 20431602.